Furthermore, the linear counterpart of the PICALM’s dysregulation influences the risk of AD development by impacting APP processing, Aβ transcytosis and tau progression, highlighting its multifaceted influence on AD pathogenesis (Ando K et al. 2022). The gene discussed is MAPT; the disease is Alzheimer disease.